Omidubicel

CHEMBL4298190 Phase 4 Aprovado Cell

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A nicotinamide-expanded cord blood stem cell therapy used as a stem cell transplant to treat blood cancers such as leukemia and lymphoma. The expansion process increases the number of stem cells available, improving engraftment speed compared to standard cord blood transplants.

Áreas Terapêuticas

Lymphoma Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A nicotinamide-expanded cord blood stem cell therapy used as a stem cell transplant to treat blood cancers such as leukemia and lymphoma. The expansion process increases the number of stem cells available, improving engraftment speed compared to standard cord blood transplants.

Yes, Omidubicel is an approved drug. It has reached clinical phase 4. It is classified as a Cell.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4298190. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Procura informações acessíveis para o paciente?

Omidubicel no PillFYI

Dados Rápidos

Sinônimos: 1

Links Externos

ChEMBL CHEMBL4298190

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.